» Articles » PMID: 38570510

Strategies to Improve Implementation of Cascade Testing in Hereditary Cancer Syndromes: a Systematic Review

Overview
Journal NPJ Genom Med
Specialty Genetics
Date 2024 Apr 3
PMID 38570510
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary cancer syndromes constitute approximately 10% of all cancers. Cascade testing involves testing of at-risk relatives to determine if they carry the familial pathogenic variant. Despite growing efforts targeted at improving cascade testing uptake, current literature continues to reflect poor rates of uptake, typically below 30%. This study aims to systematically review current literature on intervention strategies to improve cascade testing, assess the quality of intervention descriptions and evaluate the implementation outcomes of listed interventions. We searched major databases using keywords and subject heading of "cascade testing". Interventions proposed in each study were classified according to the Effective Practice and Organization of Care (EPOC) taxonomy. Quality of intervention description was assessed using the TIDieR checklist, and evaluation of implementation outcomes was performed using Proctor's Implementation Outcomes Framework. Improvements in rates of genetic testing uptake was seen in interventions across the different EPOC taxonomy strategies. The average TIDieR score was 7.3 out of 12. Items least reported include modifications (18.5%), plans to assess fidelity/adherence (7.4%) and actual assessment of fidelity/adherence (7.4%). An average of 2.9 out of 8 aspects of implementation outcomes were examined. The most poorly reported outcomes were cost, fidelity and sustainability, with only 3.7% of studies reporting them. Most interventions have demonstrated success in improving cascade testing uptake. Uptake of cascade testing was highest with delivery arrangement (68%). However, the quality of description of interventions and assessment of implementation outcomes are often suboptimal, hindering their replication and implementation downstream. Therefore, further adoption of standardized guidelines in reporting of interventions and formal assessment of implementation outcomes may help promote translation of these interventions into routine practice.

Citing Articles

The Genetic Information and Family Testing (GIFT) study: trial design and protocol.

Katz S, Abrahamse P, Hofer T, Courser R, Hodan R, Tocco R BMC Cancer. 2025; 25(1):366.

PMID: 40016666 PMC: 11869684. DOI: 10.1186/s12885-025-13744-6.


Interventions to improve pharmacists' competency in chronic disease management: a systematic review of randomized controlled trials.

Rendrayani F, Utami A, Insani W, Puspita F, Alfian S, Nguyen T BMC Med Educ. 2024; 24(1):1441.

PMID: 39696183 PMC: 11654421. DOI: 10.1186/s12909-024-06393-z.


A family-based approach to cascade genetic testing in a pediatric cancer genetics clinic.

Haider R, Desrosiers-Battu L, Scollon S, Stankiewicz P, Lupo P, Plon S Fam Cancer. 2024; 24(1):8.

PMID: 39565446 DOI: 10.1007/s10689-024-00434-8.


Innovative Implementation Strategies for Familial Hypercholesterolemia Cascade Testing: The Impact of Genetic Counseling.

Morgan K, Campbell-Salome G, Walters N, Betts M, Brangan A, Johns A J Pers Med. 2024; 14(8).

PMID: 39202032 PMC: 11355397. DOI: 10.3390/jpm14080841.

References
1.
Allen P, Pilar M, Walsh-Bailey C, Hooley C, Mazzucca S, Lewis C . Quantitative measures of health policy implementation determinants and outcomes: a systematic review. Implement Sci. 2020; 15(1):47. PMC: 7304175. DOI: 10.1186/s13012-020-01007-w. View

2.
Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E . The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Fam Cancer. 2016; 15(2):155-62. PMC: 4803813. DOI: 10.1007/s10689-015-9854-4. View

3.
Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed D . TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. J Clin Oncol. 2022; 40(18):2036-2047. PMC: 9197360. DOI: 10.1200/JCO.21.02108. View

4.
Menko F, van der Velden S, Griffioen D, Ait Moha D, Jeanson K, Hogervorst F . Does a proactive procedure lead to a higher uptake of predictive testing in families with a pathogenic BRCA1/BRCA2 variant? A family cancer clinic evaluation. J Genet Couns. 2023; 33(3):615-622. DOI: 10.1002/jgc4.1767. View

5.
Teppala S, Hodgkinson B, Hayes S, Scuffham P, Tuffaha H . A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. J Med Econ. 2022; 26(1):19-33. DOI: 10.1080/13696998.2022.2152233. View